Title |
Randomized supplementation of 4000 IU vitamin D3 daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial
|
---|---|
Published in |
Nutrition Journal, August 2017
|
DOI | 10.1186/s12937-017-0270-5 |
Pubmed ID | |
Authors |
J. B. Ernst, S. Prokop, U. Fuchs, J. Dreier, J. Kuhn, C. Knabbe, H. K. Berthold, S. Pilz, I. Gouni-Berthold, J. F. Gummert, J. Börgermann, A. Zittermann |
Abstract |
Low 25-hydroxyvitamin D (25OHD) levels (< 75 nmol/l) are inversely associated with anemia prevalence. Since anemia and low 25OHD levels are common in patients with heart failure (HF), we aimed to investigate whether vitamin D supplementation can reduce anemia prevalence in advanced HF. EVITA (Effect of Vitamin D on Mortality in Heart Failure) is a randomized, placebo-controlled clinical trial in patients with initial 25OHD levels < 75 nmol/l. Participants received either 4000 IU vitamin D3 daily or a matching placebo for 36 months. A total of 172 patients (vitamin D group: n = 85; placebo group: n = 87) were investigated in this pre-specified secondary data analysis. Hemoglobin (Hb) and other hematological parameters were measured at baseline and study termination. Assessment of between-group differences in anemia prevalence and Hb concentrations was performed at study termination, while adjusting for baseline differences. In the vitamin D and placebo group, baseline proportions of patients with anemia (Hb < 12.0 g/dL in females and < 13.0 g/dL in males) were 17.2% and 10.6%, respectively (P = 0.19). At study termination, the proportion of patients with anemia in the vitamin D and placebo groups was 32.2% and 31.8%, respectively (P > 0.99). There was no between-group difference in change in the Hb concentrations (- 0.04 g/dL [95%CI:-0.53 to 0.45 g/dL]; P = 0.87). Results regarding anemia risk and Hb concentrations were similar in the subgroup of patients with chronic kidney disease (vitamin D group: n = 26; placebo group: n = 23). Moreover, results did not differ substantially when data analysis was restricted to patients with deficient baseline 25OHD levels. A daily vitamin D supplement of 4000 IU did not reduce anemia prevalence in patients with advanced HF. Data challenge the clinical relevance of vitamin D supplementation to increase Hb levels. The study was registered at EudraCT (No. 2010-020793-42) and clinicaltrials.gov ( NCT01326650 ). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 86 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 14% |
Student > Master | 7 | 8% |
Student > Ph. D. Student | 6 | 7% |
Student > Doctoral Student | 6 | 7% |
Other | 5 | 6% |
Other | 20 | 23% |
Unknown | 30 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 33 | 38% |
Nursing and Health Professions | 6 | 7% |
Biochemistry, Genetics and Molecular Biology | 5 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Agricultural and Biological Sciences | 1 | 1% |
Other | 3 | 3% |
Unknown | 34 | 40% |